Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring ascorbic acid, vitamin c
Eligibility Criteria
Inclusion Criteria:
- Male or non-pregnant female > 18 years of age at the time of consent
- ConfirmedSARS-CoV-2 infection
- Disease severity necessitating hospitalization
- Currently taking supplemental oxygen
No anticipated need (within 24 hours) for mechanical ventilation, defined as:
- Positive clinical response to oxygen supplementation with improvement in hypoxia or
- Hypoxia improvement with bronchospasm therapy if bronchospasm present
Exclusion Criteria
- eGFR < 50
- Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Anticipated need for mechanical ventilation within 24 hours
- Pregnant or breastfeeding
- Requires home oxygen for any reason
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Treatment
Routine care
Ascorbic acid solution (Ascor®, McGuff Pharmaceuticals, Ltd.) will be added to each liter of sterile wate,r plus 1 g/L magnesium chloride to reduce burning sensation, and given parenterally over a 2-hour period. On the day of enrollment (Day 0), 0.3 g/kg will be given; Day 1 - 0.6 g/kg; Day 2 - 0.9 g/kg; Day 3 - 0.9 g/kg; Day 4 - 0.9 g/kg; Day 5 - 0.9 g/kg. After the first dose, each subsequent dose will be given 24 +/- 4 hours following the previous dose.
These subject will follow routine care and their clinical courses will be recorded only.